Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.
Shares of Travere Therapeutics took a hit Tuesday after fewer than expected patients started treatment with its kidney drug.
Q3 earnings swing to loss as revenue rises Travere Therapeutics (TVTX) just delivered third quarter 2026 numbers that pulled investor attention to both sides of the income statement. Revenue reached US$224.56 million while the company moved from profit to a net loss. The biopharma group focused on rare kidney and metabolic diseases reported a net loss of US$52.34 million for the quarter. In the same period a year earlier it had posted net income of US$25.71 million. On a per share basis,...
Travere Therapeutics has delivered a very large 3 year share price gain, which naturally puts the spotlight on whether the current valuation can be explained by its sales base. With the stock around US$49.26 after some recent pullback, the question is how that share price lines up with what the business is generating from its commercial portfolio. Travere Therapeutics has returned roughly 7x over the past 3 years, which puts a lot of weight on whether revenue today and potential future sales...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
SAN DIEGO, October 02, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI® (sparsentan) in patients with IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).
Travere Therapeutics (TVTX) said Wednesday that it received a notice of allowance from the US Patent
SAN DIEGO, September 23, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," directed to certain methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). Upon issuance, the patent is expected to provide U.S. patent coverage for certain
Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric Dube will step down from his roles as CEO and President as part of the scheduled leadership change. Bradley L. Campbell has been appointed to succeed Dr. Dube, bringing experience from the rare disease biopharmaceutical sector. This CEO and President transition at Travere Therapeutics is an important development to set alongside the rest of the analysis. We have also...
Tipranks Press Release.
Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on what investors are paying for its sales today. With the stock now reflecting years of optimism, the immediate question is how well the current valuation lines up with the revenue the business is actually generating. Over the last 3 years the share price has risen by roughly 7x, so anyone looking at Travere Therapeutics now is effectively asking how much of that move is...
SAN DIEGO, September 21, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer a
William E. Rote, Chief Research Officer, on September 15, 2026, sold 209,048 shares in Travere Thera
Eric M Dube, Director, Chief Executive Officer, on September 15, 2026, sold 400,000 shares in Traver
This is the newest page. Registered accounts read further back.